{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:12:27Z","timestamp":1788988347942,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016126","name":"Beijing Hospitals Authority","doi-asserted-by":"publisher","award":["DFL20240301"],"award-info":[{"award-number":["DFL20240301"]}],"id":[{"id":"10.13039\/100016126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20251480"],"award-info":[{"award-number":["GZC20251480"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:22:26Z","timestamp":1765725746000},"page":"1113.e1-1113.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents"],"prefix":"10.1016","volume":"32","author":[{"given":"Qiling","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-0085","authenticated-orcid":false,"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-8489","authenticated-orcid":false,"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2025.12.008_bib0001","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.008_bib0002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","article-title":"European Myeloma Network Group review and consensus statement on primary plasma cell leukemia","volume":"36","author":"Musto","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.008_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.008_bib0004","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11912-024-01563-0","article-title":"Current status on management of primary plasma cell leukemia","volume":"26","author":"Gong","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.008_bib0005","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.008_bib0006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.008_bib0007","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.008_bib0008","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2025.12.008_bib0009","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CLEP.S99463","article-title":"The Danish national multiple myeloma registry","volume":"8","author":"Gimsing","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.008_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.008_bib0011","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.008_bib0012","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek Myeloma Study Group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.008_bib0013","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1007\/s00277-024-05862-1","article-title":"Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study","volume":"103","author":"Deng","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.008_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-018-0059-6","article-title":"Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group","volume":"8","author":"Katodritou","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.008_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.008_bib0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"Evidence meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.008_bib0017","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.008_bib0018","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.008_bib0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.008_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.jtct.2025.12.008_bib0021","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.008_bib0022","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.008_bib0023","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.008_bib0024","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.008_bib0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.008_bib0026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia","volume":"28","author":"Musto","year":"2014","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.jtct.2025.12.008_bib0027","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.008_bib0028","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.008_bib0029","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.008_bib0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.008_bib0031","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.008_bib0032","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:51:55Z","timestamp":1788987115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725016665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636725016665"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}